AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03592316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Extremity Amputation Pathway
Description: Pre-operatively: Subjects will meet with social work/case management, physical therapy, anesthesiology, and the prosthetist for the following: discuss expectations and rehabilitation; pain control options and consideration for epidural or nerve block; prosthetic treatment and care timeline.~Post-operatively: Physical therapy will begin on post-op day 1 with increasing complexity through post-op day 3. On post-op day 3 the wound will be examined by the surgeon and subjects will be cleared for discharge.~Quality of life surveys will be given at several time points during post-operative care.
Study NCT03926429 — intervention group
Intervention type: OTHER
Intervention: Standardised data collection
Description: The following variables will be retrospectively assessed by medical record review using a standardised data collection form:demographics; gender, age; family or personal history of spondyloarthritis, psoriasis, uveitis, inflammatory bowel disease; clinical presentation; mono, oligo or polyarthritis, dactylitis, inflammatory joint pain, enthesopathy, axial symptoms, fever, extra-articular manifestations (conjunctivitis, anterior uveitis, circinate balanitis, skin rash); time interval between infection and musculoskeletal manifestations; causal microorganism if known, or triggering event; HLA-B27; radiographic sacroiliitis; treatments and outcomes (complete recovery at one year follow-up, relapse within 6 months after onset, or spondyloarthritis according to the ASAS criteria).
Study NCT04838730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical procedure
Description: Standard cataract extraction procedure will be performed under local anesthesia (at physician discretion) and CleaRing device will be implanted together with SeeLens AF IOL.
Study NCT02251093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lcr Regenerans
Description: Dosage: 1 vaginal capsule per day Route of administration: intravaginal Treatment duration: One 21-day cycle
Study NCT02251093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage: 1 vaginal capsule per day Route of administration: intravaginal Treatment duration: One 21-day cycle
Study NCT01497028 — intervention group
Intervention type: PROCEDURE
Intervention: PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.
Description: PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.
Study NCT00624273 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sildenafil therapy
Description: oral use
Study NCT02182934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginsana
Study NCT02182934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01541046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biogaia L. reuteri DSM 17938
Description: Freeze-dried Lactobacillus reuteri DSM 17938 suspended in oil. Brand Name Active Agent: BioGaia™
Study NCT01541046 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic Placebo
Description: Description of Placebo: contains same excipients as Active Agent, without the active ingredient
Study NCT00518596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Lactobacillus plantarum)
Description: GastroPlan capsules from a single lot will be used. The intervention consists of L. plantarum reconstituted in sterile 2.0 cc of 5% dextrose-saline, administered orally using an opaque-amber syringe.
Study NCT00370747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecabet
Description: ophthalmic solution 2.83%
Study NCT02600975 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R21 with ASO1B
Description: R21 with ASO1B
Study NCT03551990 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: whole-body electromyostimulation WB-EMS
Description: Patients of the WB-EMS group will perform whole-body electromyostimulation (WB-EMS) training sessions twice a week over a period of 8 weeks. To allow muscle recovery a break of at least 2 days between the sessions will be scheduled. To adapt the patients to the WB-EMS intervention, the training duration will be gradually increased (week 1, 12 min; increase of 2 min/week; week 5-8, 20 min). WB-EMS training sessions will include light physical exercises according to a video tutorial and individually supervised by certified physio therapists.
Study NCT01130532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Administer orally
Study NCT01130532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administer orally
Study NCT03359408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dementia Care Management (DCM)
Description: A specialised discharge management, based on Dementia Care Management (DCM; Thyrian et al. 2017, Eichler, Thyrian, Fredrich et al. 2014, Eichler, Thyrian, Dreier et al. 2014, Dreier et al. 2016, ) will be applied to subjects with cognitive impairment. Specifically qualified will conduct comprehensive data assessments during the hospital stay, assess recommendations at discharge and assess unmet needs at home. Supported by a a computerized Intervention Management (IMS) and in close cooperation with the discharging hospital, treating physicians and other care providers, they will develop, implement and monitor a treatment and care plan. Interventional home visits will take place at the participants homes.
Study NCT02603289 — intervention group
Intervention type: DEVICE
Intervention: Invisalign
Study NCT01383174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support Program
Description: * Work with a trained counselor who is a breast cancer survivor~* Meet 8 times in-person over the 8 week program with the counselor~* Counselor helps participant develop a personalized support program to help her improve her quality of life~* Receives information on breast cancer, its treatments, and stress management
Study NCT03440840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Application of a small electrical current (1-2 mA) across the head.
Study NCT03440840 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Application of a small electrical current (1-2 mA) across the head.
Study NCT03440840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based Cognitive Training
Description: Use of computer-delivered games or exercises with the goal of improving cognitive performance.
Study NCT02181127 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon-only Bionic Pancreas
Description: A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
Study NCT02181127 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Glucagon-only Bionic Pancreas
Description: A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
Study NCT00299546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injections
Study NCT00299546 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Golimumab 50 mg
Description: SC injections
Study NCT00299546 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Description: SC injections
Study NCT00299546 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Description: SC injections
Study NCT05809440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20-minute mindful breathing session
Description: A 20-minute mindful breathing session guided by a trained medical doctor. The session consisted of four 5-minute breathing exercises done consecutively. Participants were instructed to close their eyes and bring their attention to their breathing, and re-direct their attention back to their breathing once they were distracted.
Study NCT00726440 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Navigator®
Description: Patients will be encouraged to use the Navigator® all the time and to modify their treatment according to the device measurments. Patients will also follow and educational process in order to adapt insulin doses according to each sensor data
Study NCT00726440 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Navigator®
Description: Patients will follow the same educational process as group1 concerning insulin doses adaptation.The duration of the use of the devicewill be determined at the consultation every each 3 months.
Study NCT00726440 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will have their usual follow up with self-monitoring blood glucose
Study NCT03324802 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy
Study NCT03324802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03324802 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: hypofractionated radiation therapy
Study NCT01887132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Study NCT01887132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00567086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TEZAMPANEL
Description: Single Administration of: TEZAMPANEL 40 mg; TEZAMPANEL 70 mg; TEZAMPANEL 100 mg; Placebo (Sterile Water for Injection)
Study NCT03440840 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer-based Cognitive Training
Description: Use of computer-delivered games or exercises with the goal of improving cognitive performance.
Study NCT03440840 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Watching Educational Videos
Description: Watching educational videos and answering questions about them
Study NCT00644020 — intervention group
Intervention type: DRUG
Intervention: mitomycin, Fluorouracil
Description: All participants will receive 10mg mitomycin and 1g Fluorouracil through the chemoradiative pump which was transplanted during the operation, and this procedure would be executed a day before each research treatment period.
Study NCT03612778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plant-based diet
Description: Prescription of a meal plan based on unrefined plant-based foods supported by peer group meetings and dietary counselling. Change from the standard western-type nutritional pattern to a low-fat, unrefined, plant-based nutritional pattern.
Study NCT00567086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZAMPANEL
Description: Single Administration of: TEZAMPANEL 40 mg; TEZAMPANEL 70 mg; TEZAMPANEL 100 mg; Placebo (Sterile Water for Injection)
Study NCT03612778 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: Prescription of a meal plan based on Mediterranean diet pattern supported by peer group meetings and dietary counselling. Change from the standard western-type nutritional pattern to a Mediterranean nutritional pattern.
Study NCT03413124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MGL-3196 Tablet
Description: MGL-3196 in Tablet form
Study NCT03413124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MGL-3196 Capsule
Description: MGL-3196 in Capsule form
Study NCT02721602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Families Preventing Diabetes Together
Description: Families in the intervention group will be asked to participate in four in-person sessions at a local Fairview North metropolitan area clinic over the course of two months. Sessions will focus on age-appropriate nutrition and diabetes education, meal planning and cooking skills, healthful eating, and eating meals as a family. All family members will be asked to attend and will be involved in all four, two-hour sessions. The parent with diabetes will also complete one goal setting telephone call based on motivational interviewing techniques during the intervention period.
Study NCT03997669 — intervention group
Intervention type: OTHER
Intervention: Collection of pleural effusion
Description: Detection of pleural effusion
Study NCT03515824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-1697
Description: Administered by IV infusion on Day 1 of each 21-day cycle
Study NCT04470635 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Saliva sample collection
Study NCT02172144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL solution for inhalation
Study NCT02172144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 1744 CL
Study NCT02172144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin (Avalox®)
Study NCT00497757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: enriched hematopoetic stem cell infusion
Description: Enriched Hematopoetic Stem Cell Infusion
Study NCT02864563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: * Blood sample at diagnosis to evaluate MYCN amplification in plasma.~* In case of NB with a MYCN amplification, blood samples are also collected during treatment and follow-up.
Study NCT02380287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: humanized monoclonal antibody against human IL-17
Study NCT02426840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose vitamin D and calcium
Description: participants will receive a FDC tablet containing 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3. This drug will be administered as 1 tablet orally twice daily and is to be taken with food. In addition, participants will receive vitamin D2 capsule containing 20,000 IU of ergocalciferol, which will be administered as 1 capsule orally once weekly at any time (not related with meal).
Study NCT02426840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal dose vitamin D and calcium
Description: participants will receive a FDC tablet containing 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3. This drug will be administered as 1 tablet orally twice daily and is to be taken with food
Study NCT00370747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecabet
Description: ophthalmic solution 3.70%
Study NCT01683539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Thinking Skills for Work Program
Description: The Thinking Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, computerized cognitive practice, compensatory strategy training, and integration of cognitive and work services.
Study NCT01683539 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Cognitive Skills for Work Program
Description: The Cognitive Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, compensatory strategy training, and integration of cognitive and work services.
Study NCT02303093 — intervention group
Intervention type: BIOLOGICAL
Intervention: Octagam IVIG 5% or 10%
Description: Octagam IVIG 5% or 10%
Study NCT02303093 — intervention group
Intervention type: BIOLOGICAL
Intervention: Panzyga
Description: Panzyga
Study NCT00539994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retapamulin
Description: 200mg BID retapamulin 3 days
Study NCT00539994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retapamulin
Description: 200mg BID retapamulin 5 days
Study NCT00539994 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mg BID placebo 5 days
Study NCT04579471 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 IgG
Description: Collection of clinical variables, assessment of IgG antibodies for SARS-CoV-2, plasma collection for translational immunology studies
Study NCT02214641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilient, Empowered, Active Living with Diabetes
Description: Individualized lifestyle intervention incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants receive a total of 10-16 hours of intervention by a licensed occupational therapist with training in diabetes education, motivational interviewing and the REAL Diabetes intervention protocol.
Study NCT02214641 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Control
Description: Participants will receive a packet of informational materials about diabetes, and receive periodic follow-up phone calls to match for attention dose. The packet of materials will be delivered in an initial home visit. Follow-up phone calls will occur at approximately two week intervals to inquire whether participants have reviewed specific sections of the intervention materials, and clarify information included in the packet.
Study NCT03424538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: 5-week-long intervention, physiotherapy, stretching, walking preparation, strengthening
Study NCT00370747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01289899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR-A-657
Description: 120, 360mg or placebo 7days
Study NCT01125956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned a peer counselor
Description: Dyads will be given $20 per month if they have contact 4 or more times during a month.
Study NCT01125956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Participants will be given $100 for reduction of HbA1c by 1 point in a 6 month period and $200 for reduction by 2 points.
Study NCT00654381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356
Description: 5 mg/daily
Study NCT00654381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356
Description: 10 mg/daily
Study NCT00654381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: voglibose placebo
Description: three times daily
Study NCT00654381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BI 1356 placebo
Description: once daily
Study NCT00654381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: voglibose
Description: 0.6 mg/daily
Study NCT02189187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Study NCT02189187 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Study NCT00832208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal amphotericin B (Ambisome)
Description: 21.0 mg/kg total dose. Given iv as 3mg/kg/day on days 1,2,3,4,5, and 14 and 21
Study NCT00832208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (Ambisome)
Description: liposomal amphotericin b given intravenously as single dose at 7.5 mg/kg increasing to 10, 12.5 and 15.0mg/kg depending on results of interim analyses.
Study NCT03604055 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endobronchial hamartomas treatment
Description: General anesthesia was administered by an intravenous anesthesia technique. Patients were intubated with a rigid bronchoscope. Debulking procedures were performed by mechanical tumor resection (MTR) using the tip of the rigid bronchoscope, rigid pliers or argon plasma coagulation assisted MTR or cryorecanalization or electrocautery - snare probe. An innovation of our study was that cryotherapy was performed in the regions where the lesions originated after debulking
Study NCT01067352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (r-hGH)
Description: Recombinant human GH were administered subcutaneously (s.c) at the daily dose of 0.067 mg/kg of body weight to Group A1.
Study NCT03448003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cancer Prevention
Description: Attend IO prevention program
Study NCT00365599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suberoylanilide hydroxamic acid (SAHA, Vorinostat)
Description: Vorinostat will be used to potentiate the effects of tamoxifen or overcome tamoxifen resistance. All patients will receive vorinostat at 400 mg by mouth (po) daily for 3 out of 4 weeks. Responses will be assessed after 2 cycles (8 weeks + 4 days).
Study NCT03448003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03448003 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00723606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular ziprasidone mesylate
Description: The recommended dose is 10 to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day for 3 days.